Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Won You Kang"'
Autor:
Joo-Yong Hahn, Young Bin Song, Ju-Hyeon Oh, Deok-Kyu Cho, Jin Bae Lee, Joon-Hyung Doh, Sang-Hyun Kim, Jin-Ok Jeong, Jang-Ho Bae, Byung-Ok Kim, Jang Hyun Cho, Il-Woo Suh, Doo-il Kim, Hoon-Ki Park, Jong-Seon Park, Woong Gil Choi, Wang Soo Lee, Jihoon Kim, Ki Hong Choi, Taek Kyu Park, Joo Myung Lee, Jeong Hoon Yang, Jin-Ho Choi, Seung-Hyuk Choi, Hyeon-Cheol Gwon, Jong-Young Lee, Hun Sik Park, Jin-Yong Hwang, Seung-Ho Hur, Seung-Woon Rha, Sang Cheol Cho, Won You Kang, Seong-Hoon Lim, Moo Hyun Kim, Kwang Soo Cha, Rak Kyung Choi, In-Ho Chae, Woo Jin Jang, Yong Hawn Park, Woo Jung Chun, Jae Woong Choi, Myung Ho Jeong, Seung Ho Kang, Kyung-Ju Ahn
Publikováno v:
Lancet (London, England). 391(10127)
Summary Background Current guidelines recommend dual antiplatelet therapy (DAPT) of aspirin plus a P2Y12 inhibitor for at least 12 months after implantation of drug-eluting stents (DES) in patients with acute coronary syndrome. However, available dat
Autor:
Seung Uk Lee, Doo Sun Sim, Joon Woo Kim, Jei Keon Chae, Jay Young Rhew, Youngkeun Ahn, Sang Rok Lee, Myung Ho Jeong, Keun Ho Park, Su Hyun Kim, Kyeong Ho Yun, Jong Pil Park, Won You Kang, Ju Han Kim, Seok Kyu Oh, Jang Hyun Cho, Dong Goo Kang, Sun Ho Hwang, Young Joon Hong
Publikováno v:
Chonnam Medical Journal
The Endeavor Resolute® (ER) is a zotarolimus-eluting stent (ZES) with a biocompatible BioLinx polymer. This study prospectively compared the clinical outcomes of 2 versions of ZES, ER and Endeavor Sprint® (ES), in patients with multivessel disease.